ATE374826T1 - Chimäre polypeptide und ihre verwendung - Google Patents

Chimäre polypeptide und ihre verwendung

Info

Publication number
ATE374826T1
ATE374826T1 AT04727873T AT04727873T ATE374826T1 AT E374826 T1 ATE374826 T1 AT E374826T1 AT 04727873 T AT04727873 T AT 04727873T AT 04727873 T AT04727873 T AT 04727873T AT E374826 T1 ATE374826 T1 AT E374826T1
Authority
AT
Austria
Prior art keywords
dna
activity
activities
chimeric molecules
region
Prior art date
Application number
AT04727873T
Other languages
German (de)
English (en)
Inventor
Christian Kuehne
Andras Simoncsits
Original Assignee
Icgeb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icgeb filed Critical Icgeb
Application granted granted Critical
Publication of ATE374826T1 publication Critical patent/ATE374826T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
AT04727873T 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung ATE374826T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.

Publications (1)

Publication Number Publication Date
ATE374826T1 true ATE374826T1 (de) 2007-10-15

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727873T ATE374826T1 (de) 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung

Country Status (16)

Country Link
US (3) US20060292629A1 (https=)
EP (1) EP1616011B1 (https=)
JP (2) JP4794432B2 (https=)
KR (2) KR101360781B1 (https=)
CN (1) CN100584950C (https=)
AT (1) ATE374826T1 (https=)
AU (1) AU2004230254B2 (https=)
CA (1) CA2522525A1 (https=)
CY (1) CY1107115T1 (https=)
DE (1) DE602004009301T2 (https=)
DK (1) DK1616011T3 (https=)
ES (1) ES2293247T3 (https=)
IT (1) ITMI20030821A1 (https=)
PL (1) PL1616011T3 (https=)
PT (1) PT1616011E (https=)
WO (1) WO2004092194A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
ATE464395T1 (de) * 2005-02-18 2010-04-15 Astrazeneca Ab Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
CA2939694A1 (en) 2014-02-17 2015-08-20 Universite Claude Bernard Lyon 1 Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
CA3019629A1 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
WO2017205852A2 (en) * 2016-05-27 2017-11-30 Synthex, Inc. Protein interfaces
WO2017211941A1 (en) * 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein b
CA3067382A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
KR102503130B1 (ko) 2017-10-27 2023-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023111213A1 (en) 2021-12-16 2023-06-22 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
WO2000046386A2 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
EP2806025B1 (en) * 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Also Published As

Publication number Publication date
CY1107115T1 (el) 2012-01-25
US20150018409A1 (en) 2015-01-15
JP2006523448A (ja) 2006-10-19
EP1616011B1 (en) 2007-10-03
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
US20060292629A1 (en) 2006-12-28
KR20110074948A (ko) 2011-07-04
WO2004092194A3 (en) 2005-03-17
EP1616011A2 (en) 2006-01-18
CN1768142A (zh) 2006-05-03
JP4794432B2 (ja) 2011-10-19
DE602004009301D1 (de) 2007-11-15
KR101360781B1 (ko) 2014-04-24
ES2293247T3 (es) 2008-03-16
KR20060003029A (ko) 2006-01-09
KR101247704B1 (ko) 2013-03-26
US20110033384A1 (en) 2011-02-10
DK1616011T3 (da) 2008-02-04
ITMI20030821A1 (it) 2004-10-19
AU2004230254B2 (en) 2008-10-02
DE602004009301T2 (de) 2008-07-17
AU2004230254A1 (en) 2004-10-28
JP2011182792A (ja) 2011-09-22
CA2522525A1 (en) 2004-10-28
CN100584950C (zh) 2010-01-27
WO2004092194A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
ATE374826T1 (de) Chimäre polypeptide und ihre verwendung
Passioura et al. A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets
WO2005108415A8 (en) Membrane associated molecules
EA200700408A1 (ru) Транспортный белок для доставки химических соединений в нервные клетки
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
MX2008001509A (es) Peptidos protectores de tejido y sus usos.
WO2005046709A3 (en) Tgf - beta binding and supported peptides
WO2006024547A3 (en) Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
MY162624A (en) Antibodies directed to her-3 and uses thereof
CA2345903A1 (en) Molecular pathogenicide mediated plant disease resistance
WO2006128668A3 (en) Coagulation factor x polypeptides with modified activation properties
DK0914339T3 (da) Ret ligand 3 (RetL3) til stimulering af neural og renal vækst
Miura et al. Cyclic β2, 3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease
WO2006029078A3 (en) Targeting transducible molecules to specific cell types
Katoh et al. Ribosomal incorporation of negatively charged d-α-and N-methyl-l-α-amino acids enhanced by EF-Sep
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
Wei et al. Immobilized acyl-transfer molecular reactors enable the solid-phase synthesis of sterically hindered peptides
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
ATE471169T1 (de) Engineering mit homing-faktoren
WO2002044409A3 (en) Substrate linked directed evolution (slide)
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
WO2008094316A3 (en) Novel branchiostoma derived fluorescent proteins
DE60036548D1 (de) Neue kalium-kanäle und dafür kodierende gene
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1616011

Country of ref document: EP

EEIH Change in the person of patent owner